person · Reporting owner

Hayden Michael R

Disclosed activity across 5 companies

Tapewire entity: 20312
SEC CIK: 0001352908

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AbCellera Biologics Inc.ABCL · Entity 4118	Director	August 24, 2026	August 24, 2026
Aurinia Pharmaceuticals Inc.AUPH · Entity 4463	Director	January 29, 2021	February 02, 2021
IONIS PHARMACEUTICALS INCIONS · Entity 1182	Director	July 30, 2026	July 31, 2026
Xenon Pharmaceuticals Inc.XENE · Entity 2602	Director	June 03, 2021	June 04, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AbCellera Biologics Inc.

Report date August 24, 2026 · Filed August 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	IndirectSee footnote	1,373,397	Reported balance After 2026-08-24 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-08-24 · Purchase · Acquired 53,613 · Balance 1,373,397 F1: The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $10.49 to $10.70. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. F2: These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.
Common SharesSEC Table I · non-derivative	IndirectBy spouse	118,245	Reported balance Holding disclosure · report date 2026-08-24 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 118,245

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $10.49 to $10.70. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

F2: These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.

Aurinia Pharmaceuticals Inc.

Report date January 29, 2021 · Filed February 02, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	95,000	Ending reported balance After 2021-01-29 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2021-01-29 · Exercise / conversion · Acquired 50,000 · Balance 50,000 F1: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Row 2 · 2021-01-29 · Exercise / conversion · Acquired 30,000 · Balance 80,000 F1: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Row 3 · 2021-01-29 · Exercise / conversion · Acquired 15,000 · Balance 95,000 F1: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.44 · Expires 2028-02-22	Direct	0	Reported balance After 2021-01-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-01-29 · Exercise / conversion · Disposed 50,000 · Balance 0 F1: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F2: The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.06 · Expires 2029-01-29	Direct	0	Reported balance After 2021-01-29 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-01-29 · Exercise / conversion · Disposed 30,000 · Balance 0 F1: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F2: The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.42 · Expires 2029-07-03	Direct	0	Reported balance After 2021-01-29 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-01-29 · Exercise / conversion · Disposed 15,000 · Balance 0 F1: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F2: The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.

F2: The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date.

IONIS PHARMACEUTICALS INC

Report date July 30, 2026 · Filed July 31, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Indirectby Spouse	24,000	Last balance in matching sequence After 2026-07-31 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2026-07-30 · Purchase · Acquired 15,000 · Balance 19,000 F1: The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $53.00 to $53.58 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) on this Form 4. F2: These securities are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. Row 2 · 2026-07-31 · Purchase · Acquired 5,000 · Balance 24,000 F3: The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $51.45 to $51.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) on this Form 4. F2: These securities are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2.
Common StockSEC Table I · non-derivative	Direct	54,298	Reported balance Holding disclosure · report date 2026-07-30 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 54,298

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $53.00 to $53.58 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) on this Form 4.

F2: These securities are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2.

F3: The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $51.45 to $51.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) on this Form 4.

Xenon Pharmaceuticals Inc.

Report date June 03, 2021 · Filed June 04, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.56 · Expires 2031-06-02	Direct	10,000	Reported balance After 2021-06-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-06-03 · Grant · Acquired 10,000 · Balance 10,000 F1: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

89bio, Inc.

Report date October 30, 2025 · Filed October 31, 2025

Section 16 reporting ended · disclosed 2025-10-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-10-30 transaction · row 1 1 source row Row 1 · 2025-10-30 · Other · Disposed 80,904 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement") (the Closing Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2025-10-30 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2025-10-30 · Other · Disposed 103,978 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement") (the Closing Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F3: These shares are held directly by Genworks 2 Consulting Inc., over which the Reporting Person's wife has sole voting and investment power.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2025-10-30 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2025-10-30 · Other · Disposed 61,538 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement") (the Closing Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F4: These shares are held directly by The Hayden Family Trust, over which the Reporting Person's wife has sole voting and investment power.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2028-11-09	Direct	Reported balance After 2025-10-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-10-30 · Disposition to issuer · Disposed 27,647 · Balance 0 F5: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2029-01-30	Direct	Reported balance After 2025-10-30 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-10-30 · Disposition to issuer · Disposed 2,933 · Balance 0 F5: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.11 · Expires 2029-07-30	Direct	Reported balance After 2025-10-30 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-10-30 · Disposition to issuer · Disposed 22,730 · Balance 0 F5: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.40 · Expires 2030-04-05	Direct	Reported balance After 2025-10-30 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-10-30 · Disposition to issuer · Disposed 7,000 · Balance 0 F5: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.29 · Expires 2030-06-22	Direct	Reported balance After 2025-10-30 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-10-30 · Disposition to issuer · Disposed 7,000 · Balance 0 F5: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.16 · Expires 2031-04-15	Direct	Reported balance After 2025-10-30 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-10-30 · Disposition to issuer · Disposed 12,500 · Balance 0 F5: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.64 · Expires 2032-05-16	Direct	Reported balance After 2025-10-30 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-10-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.70 · Expires 2033-02-09	Direct	Reported balance After 2025-10-30 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2025-10-30 · Disposition to issuer · Disposed 27,400 · Balance 0 F5: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.98 · Expires 2034-02-01	Direct	Reported balance After 2025-10-30 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2025-10-30 · Disposition to issuer · Disposed 45,150 · Balance 0 F5: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.60 · Expires 2035-02-01	Direct	Reported balance After 2025-10-30 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2025-10-30 · Disposition to issuer · Disposed 56,400 · Balance 0 F5: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]

F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement") (the Closing Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

F3: These shares are held directly by Genworks 2 Consulting Inc., over which the Reporting Person's wife has sole voting and investment power.

F4: These shares are held directly by The Hayden Family Trust, over which the Reporting Person's wife has sole voting and investment power.

F5: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6]

F6: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7]

F7: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 15, 2020 Filed Oct 19, 2020 21:50 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	1,778	$0.00	$0.00	Disclosure SEC source: 0000874015-20-000136 · edgar.xml · nonDerivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document
July 01, 2020 Filed Jul 6, 2020 22:48 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantDirector Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $60.20	$0.00	Disclosure SEC source: 0000874015-20-000112 · edgar.xml · derivative · entry 4 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-30 F5 · derivative.exercise_date: Grant of July 1, 2020 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2020. F5 · derivative.expiration_date: Grant of July 1, 2020 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2020. Read SEC document
July 01, 2020 Filed Jul 6, 2020 22:48 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantRestricted Stock Units · Derivative	5,333	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-20-000112 · edgar.xml · derivative · entry 3 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,333 Underlying: Common Stock · 5,333 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: Grant of July 1, 2020 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2020. F4 · derivative.expiration_date: Grant of July 1, 2020 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2020. Read SEC document
July 01, 2020 Filed Jul 6, 2020 22:48 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Units · Derivative	1,778	$0.00	$0.00	Disclosure SEC source: 0000874015-20-000112 · edgar.xml · derivative · entry 2 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,332 Underlying: Common Stock · 1,778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
July 01, 2020 Filed Jul 6, 2020 22:48 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	1,778	$0.00	$0.00	Disclosure SEC source: 0000874015-20-000112 · edgar.xml · nonDerivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document
June 22, 2020 Filed Jul 14, 2020 21:01 UTC	89bio, Inc. ETNB · Entity 73682	GrantStock Option (Right to Buy) · Derivative	7,000	$0.00 Strike: $24.29	$0.00	Disclosure SEC source: 0000899243-20-019089 · doc4.xml · derivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2030-06-22 F1 · derivative.exercise_date: This option represents a right to purchase a total of 7,000 shares of the Issuer's Common Stock, which will vest in full on June 22, 2021, subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document
June 01, 2020 Filed Jun 2, 2020 21:09 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $13.11	$0.00	Disclosure SEC source: 0001209191-20-033627 · doc4.xml · derivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2030-05-31 F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date. Read SEC document
April 05, 2020 Filed Apr 7, 2020 20:15 UTC	89bio, Inc. ETNB · Entity 73682	GrantStock Option (Right to Buy) · Derivative	7,000	$0.00 Strike: $21.40	$0.00	Disclosure SEC source: 0000899243-20-010401 · doc4.xml · derivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2030-04-05 F1 · derivative.exercise_date: This option represents a right to purchase a total of 7,000 shares of the Issuer's Common Stock, one third of which will vest on April 5, 2021, with the remaining two thirds vesting in equal monthly installments over the following two years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
November 13, 2019 Filed Nov 14, 2019 00:02 UTC	89bio, Inc. ETNB · Entity 73682	ConversionSeries A Preferred Stock · Derivative	366,667	$0.00	$0.00	Disclosure SEC source: 0000899243-19-027220 · doc4.xml · derivative · entry 3 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 58,978 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date. F2 · derivative.exercise_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date. F2 · derivative.expiration_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date. F3 · ownership.nature: These shares are held directly by Genworks 2 Consulting Inc., over which the Reporting Person's wife has sole voting and investment power. Read SEC document
November 13, 2019 Filed Nov 14, 2019 00:02 UTC	89bio, Inc. ETNB · Entity 73682	ConversionCommon Stock	58,978	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-027220 · doc4.xml · nonDerivative · entry 2 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 77,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date. F3 · ownership.nature: These shares are held directly by Genworks 2 Consulting Inc., over which the Reporting Person's wife has sole voting and investment power. Read SEC document
November 11, 2019 Filed Nov 14, 2019 00:02 UTC	89bio, Inc. ETNB · Entity 73682	PurchaseCommon Stock	18,750	$16.00	$300,000.00	Disclosure SEC source: 0000899243-19-027220 · doc4.xml · nonDerivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 18,750 F1 · shares: On November 11, 2019, Genworks 2 Consulting Inc. purchased 18,750 shares of the Issuer's common stock at a price of $16.00 per share in the Issuer's initial public offering. F3 · ownership.nature: These shares are held directly by Genworks 2 Consulting Inc., over which the Reporting Person's wife has sole voting and investment power. Read SEC document
October 15, 2019 Filed Oct 17, 2019 21:52 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Units · Derivative	1,778	$0.00	$0.00	Disclosure SEC source: 0000874015-19-000125 · edgar.xml · derivative · entry 2 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,332 Underlying: Common Stock · 1,778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document
October 15, 2019 Filed Oct 17, 2019 21:52 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	1,778	$0.00	$0.00	Disclosure SEC source: 0000874015-19-000125 · edgar.xml · nonDerivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document
September 16, 2019 Filed Sep 18, 2019 22:35 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $9.44	$0.00	Disclosure SEC source: 0001209191-19-050133 · doc4.xml · derivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2029-09-15 F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date. Read SEC document
July 01, 2019 Filed Jul 3, 2019 22:57 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantDirector Stock Option (right to buy) · Derivative	16,000	$0.00 Strike: $64.80	$0.00	Disclosure SEC source: 0000874015-19-000110 · edgar.xml · derivative · entry 2 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2029-06-30 F3 · derivative.exercise_date: Grant of July 1, 2019 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 1, 2020. The option shall be fully vested and exercisable on July 1, 2023. The option is exercisable to 0 shares on July 1, 2019. F3 · derivative.expiration_date: Grant of July 1, 2019 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 1, 2020. The option shall be fully vested and exercisable on July 1, 2023. The option is exercisable to 0 shares on July 1, 2019. Read SEC document
July 01, 2019 Filed Jul 3, 2019 22:57 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantRestricted Stock Units · Derivative	7,110	$0.00	$0.00	Disclosure SEC source: 0000874015-19-000110 · edgar.xml · derivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,110 Underlying: Common Stock · 7,110 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F2 · derivative.exercise_date: Grant of July 1, 2019 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 1, 2020. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 1, 2023. The RSU is vested as to 0 shares on July 1, 2019. F2 · derivative.expiration_date: Grant of July 1, 2019 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 1, 2020. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 1, 2023. The RSU is vested as to 0 shares on July 1, 2019. Read SEC document
March 19, 2019 Filed Mar 20, 2019 21:13 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	Exercise / conversionStock Option (Right to Buy) · Derivative	20,576	$0.00 Strike: $3.38	$0.00	Disclosure SEC source: 0000899243-19-008569 · doc4.xml · derivative · entry 4 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Genworks Inc. Disclosed balance after: 0 Underlying: Common Shares · 20,576 shares Expires 2019-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F2 · derivative.exercise_date: The shares subject to the option fully vested on September 1, 2013. F3 · ownership.nature: Michael Hayden is the president and principal beneficial shareholder of Genworks Inc. Read SEC document
March 19, 2019 Filed Mar 20, 2019 21:13 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	Exercise / conversionCommon Shares	20,576	$3.38	$69,546.88	Disclosure SEC source: 0000899243-19-008569 · doc4.xml · nonDerivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Genworks Inc. Disclosed balance after: 50,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F3 · ownership.nature: Michael Hayden is the president and principal beneficial shareholder of Genworks Inc. Read SEC document
March 11, 2019 Filed Mar 12, 2019 21:00 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	GiftCommon Shares	17,337	$0.00	$0.00	Disclosure SEC source: 0000899243-19-007264 · doc4.xml · nonDerivative · entry 2 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 114,403 Read SEC document
March 11, 2019 Filed Mar 12, 2019 21:00 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	GiftCommon Shares	24,045	$0.00	$0.00	Disclosure SEC source: 0000899243-19-007264 · doc4.xml · nonDerivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,562 F1 · kind: 6,708 of the shares were gifted to family members that do not share the reporting person's household. Read SEC document
October 15, 2018 Filed Oct 16, 2018 00:51 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantRestricted Stock Units · Derivative	7,110	$0.00	$0.00	Disclosure SEC source: 0000874015-18-000119 · edgar.xml · derivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,110 Underlying: Common Stock · 7,110 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F2 · derivative.exercise_date: Grant of October 15, 2018 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on October 15, 2019. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on October 15, 2022. The RSU is vested as to 0 shares on October 15, 2018. F2 · derivative.expiration_date: Grant of October 15, 2018 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on October 15, 2019. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on October 15, 2022. The RSU is vested as to 0 shares on October 15, 2018. Read SEC document
September 20, 2018 Filed Sep 25, 2018 00:14 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantDirector Stock Option (right to buy) · Derivative	32,000	$0.00 Strike: $50.80	$0.00	Disclosure SEC source: 0000874015-18-000115 · edgar.xml · derivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2028-09-19 F1 · derivative.exercise_date: Grant of September 20, 2018 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on September 20, 2019. The option shall be fully vested and exercisable on September 20, 2022. The option is exercisable to 0 shares on September 20, 2018. F1 · derivative.expiration_date: Grant of September 20, 2018 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on September 20, 2019. The option shall be fully vested and exercisable on September 20, 2022. The option is exercisable to 0 shares on September 20, 2018. Read SEC document
June 04, 2018 Filed Jun 5, 2018 20:40 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $6.20	$0.00	Disclosure SEC source: 0001171843-18-004456 · form4.xml · derivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2028-06-03 F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date. Read SEC document
February 22, 2018 Filed Mar 1, 2018 23:25 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	GiftCommon Shares	21,180	$0.00	$0.00	Disclosure SEC source: 0001171843-18-001619 · f4_hayden022318.xml · nonDerivative · entry 2 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 97,066 Read SEC document
February 22, 2018 Filed Mar 1, 2018 23:25 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	GiftCommon Shares	29,580	$0.00	$0.00	Disclosure SEC source: 0001171843-18-001619 · f4_hayden022318.xml · nonDerivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,607 F1 · kind: 8,400 of these shares were gifted to family members that do not share the reporting person's household. Read SEC document
August 14, 2017 Filed Aug 14, 2017 22:06 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	PurchaseCommon Shares	15,000	$2.75	$41,247.00	Disclosure SEC source: 0001171843-17-005068 · formfour.xml · nonDerivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,187 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $2.745 to $2.75, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document
June 01, 2017 Filed Jun 2, 2017 20:56 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	GrantStock Option (Right to Buy) · Derivative	3,500	$0.00 Strike: $3.85	$0.00	Disclosure SEC source: 0001171843-17-003442 · formfour.xml · derivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Shares · 3,500 shares Expires 2027-05-31 F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date. Read SEC document
March 14, 2017 Filed Mar 15, 2017 23:53 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	Exercise / conversionStock Option (Right to Buy) · Derivative	3,086	$0.00 Strike: $3.56	$0.00	Disclosure SEC source: 0001171843-17-001550 · f4_hayden031517.xml · derivative · entry 13 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Genworks Inc. Disclosed balance after: 0 Underlying: Common Shares · 3,086 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2013. F7 · ownership.nature: Michael Hayden is the president and principal beneficial shareholder of Genworks Inc. Read SEC document
March 14, 2017 Filed Mar 15, 2017 23:53 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	Exercise / conversionStock Option (Right to Buy) · Derivative	4,629	$0.00 Strike: $3.07	$0.00	Disclosure SEC source: 0001171843-17-001550 · f4_hayden031517.xml · derivative · entry 12 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Genworks Inc. Disclosed balance after: 0 Underlying: Common Shares · 4,629 shares Expires 2018-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F6 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2012. F7 · ownership.nature: Michael Hayden is the president and principal beneficial shareholder of Genworks Inc. Read SEC document
March 14, 2017 Filed Mar 15, 2017 23:53 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	Exercise / conversionStock Option (Right to Buy) · Derivative	4,115	$0.00 Strike: $3.77	$0.00	Disclosure SEC source: 0001171843-17-001550 · f4_hayden031517.xml · derivative · entry 11 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Genworks Inc. Disclosed balance after: 0 Underlying: Common Shares · 4,115 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F5 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2011. F7 · ownership.nature: Michael Hayden is the president and principal beneficial shareholder of Genworks Inc. Read SEC document
March 14, 2017 Filed Mar 15, 2017 23:53 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	Exercise / conversionStock Option (Right to Buy) · Derivative	5,144	$0.00 Strike: $3.67	$0.00	Disclosure SEC source: 0001171843-17-001550 · f4_hayden031517.xml · derivative · entry 10 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,144 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F4 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2014. Read SEC document
March 14, 2017 Filed Mar 15, 2017 23:53 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	Exercise / conversionStock Option (Right to Buy) · Derivative	25,720	$0.00 Strike: $3.76	$0.00	Disclosure SEC source: 0001171843-17-001550 · f4_hayden031517.xml · derivative · entry 9 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 25,720 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2013. Read SEC document
March 14, 2017 Filed Mar 15, 2017 23:53 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	Exercise / conversionStock Option (Right to Buy) · Derivative	18,004	$0.00 Strike: $3.70	$0.00	Disclosure SEC source: 0001171843-17-001550 · f4_hayden031517.xml · derivative · entry 8 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 18,004 shares Expires 2018-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F2 · derivative.exercise_date: The shares subject to the option fully vested on May 31, 2011. Read SEC document
March 14, 2017 Filed Mar 15, 2017 23:53 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	Exercise / conversionCommon Shares	3,086	$3.56	$10,986.16	Disclosure SEC source: 0001171843-17-001550 · f4_hayden031517.xml · nonDerivative · entry 6 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Genworks Inc. Disclosed balance after: 30,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F7 · ownership.nature: Michael Hayden is the president and principal beneficial shareholder of Genworks Inc. Read SEC document
March 14, 2017 Filed Mar 15, 2017 23:53 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	Exercise / conversionCommon Shares	4,629	$3.07	$14,211.03	Disclosure SEC source: 0001171843-17-001550 · f4_hayden031517.xml · nonDerivative · entry 5 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Genworks Inc. Disclosed balance after: 27,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F7 · ownership.nature: Michael Hayden is the president and principal beneficial shareholder of Genworks Inc. Read SEC document
March 14, 2017 Filed Mar 15, 2017 23:53 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	Exercise / conversionCommon Shares	4,115	$3.77	$15,513.55	Disclosure SEC source: 0001171843-17-001550 · f4_hayden031517.xml · nonDerivative · entry 4 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Genworks Inc. Disclosed balance after: 22,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F7 · ownership.nature: Michael Hayden is the president and principal beneficial shareholder of Genworks Inc. Read SEC document
March 14, 2017 Filed Mar 15, 2017 23:53 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	Exercise / conversionCommon Shares	5,144	$3.67	$18,878.48	Disclosure SEC source: 0001171843-17-001550 · f4_hayden031517.xml · nonDerivative · entry 3 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document
March 14, 2017 Filed Mar 15, 2017 23:53 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	Exercise / conversionCommon Shares	25,720	$3.76	$96,707.20	Disclosure SEC source: 0001171843-17-001550 · f4_hayden031517.xml · nonDerivative · entry 2 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document
March 14, 2017 Filed Mar 15, 2017 23:53 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	Exercise / conversionCommon Shares	18,004	$3.70	$66,614.80	Disclosure SEC source: 0001171843-17-001550 · f4_hayden031517.xml · nonDerivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.